Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13 years.

Zeng Q, Vogtmann E, Jia MM, Parascandola M, Li JB, Wu YL, Feng QF, Zou XN.

Thorac Cancer. 2019 Aug;10(8):1717-1724. doi: 10.1111/1759-7714.13141. Epub 2019 Jul 10.

2.

JUUL from the USA to Indonesia: implications for expansion to LMICs.

Orlan EN, Parascandola M, Grana R.

Tob Control. 2019 Jul 5. pii: tobaccocontrol-2019-054979. doi: 10.1136/tobaccocontrol-2019-054979. [Epub ahead of print] No abstract available.

PMID:
31278082
3.

Tobacco and the lung cancer epidemic in China.

Parascandola M, Xiao L.

Transl Lung Cancer Res. 2019 May;8(Suppl 1):S21-S30. doi: 10.21037/tlcr.2019.03.12. Review.

4.

Economic burden of lung cancer attributable to smoking in China in 2015.

Shi JF, Liu CC, Ren JS, Parascandola M, Zheng R, Tang W, Huang HY, Li F, Wang L, Su K, Li N, Zhang K, Chen WQ, Wu N, Zou XN, Liu GX, Dai M.

Tob Control. 2019 May 9. pii: tobaccocontrol-2018-054767. doi: 10.1136/tobaccocontrol-2018-054767. [Epub ahead of print]

PMID:
31073096
5.

Comparative analysis of diet and tobacco use among households in Bangladesh.

Virk-Baker M, Husain MJ, Parascandola M.

Tob Prev Cessat. 2019 Mar;5:12. doi: 10.18332/tpc/105599.

PMID:
31058247
6.

Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures.

Mehrotra R, Yadav A, Sinha DN, Parascandola M, John RM, Ayo-Yusuf O, Nargis N, Hatsukami DK, Warnakulasuriya S, Straif K, Siddiqi K, Gupta PC.

Lancet Oncol. 2019 Apr;20(4):e208-e217. doi: 10.1016/S1470-2045(19)30084-1. Review.

PMID:
30942182
7.

Provincial-level cancer burden attributable to active and second-hand smoking in China.

Xia C, Zheng R, Zeng H, Zhou M, Wang L, Zhang S, Zou X, Sun K, Yang Z, Li H, Parascandola M, Islami F, Chen W.

Tob Control. 2018 Oct 15. pii: tobaccocontrol-2018-054583. doi: 10.1136/tobaccocontrol-2018-054583. [Epub ahead of print]

PMID:
30322976
8.

The crowding-out effect of tobacco expenditure on household spending patterns in Bangladesh.

Husain MJ, Datta BK, Virk-Baker MK, Parascandola M, Khondker BH.

PLoS One. 2018 Oct 9;13(10):e0205120. doi: 10.1371/journal.pone.0205120. eCollection 2018.

9.

Smoking and HIV in Sub-Saharan Africa: A 25-Country Analysis of the Demographic Health Surveys.

Murphy JD, Liu B, Parascandola M.

Nicotine Tob Res. 2019 Jul 17;21(8):1093-1102. doi: 10.1093/ntr/nty176.

PMID:
30165688
10.

Perception and Current Use of E-cigarettes Among Youth in China.

Xiao L, Parascandola M, Wang C, Jiang Y.

Nicotine Tob Res. 2018 Jul 20. doi: 10.1093/ntr/nty145. [Epub ahead of print]

PMID:
30053201
11.

The impact and relevance of tobacco control research in low-and middle-income countries globally and to the US.

Berg CJ, Fong GT, Thrasher JF, Cohen JE, Maziak W, Lando H, Drope J, Mejia R, Barnoya J, Nakkash R, Salloum RG, Parascandola M.

Addict Behav. 2018 Dec;87:162-168. doi: 10.1016/j.addbeh.2018.07.012. Epub 2018 Jul 17.

12.

Secondhand smoke exposure during pregnancy: a cross-sectional analysis of data from Demographic and Health Survey from 30 low-income and middle-income countries.

Reece S, Morgan C, Parascandola M, Siddiqi K.

Tob Control. 2019 Jul;28(4):420-426. doi: 10.1136/tobaccocontrol-2018-054288. Epub 2018 Jul 19.

PMID:
30026189
13.

Strengthening Policy-Relevant Tobacco Research Capacity in Low- and Middle-Income Countries: Challenges, Opportunities, and Lessons Learned.

Berg CJ, Thrasher JF, Barnoya J, Cohen JE, Maziak W, Lando H, Drope J, Mejia R, Foley K, Nakkash R, Fong GT, Kupfer LE, Sturke R, Parascandola M.

Nicotine Tob Res. 2019 Jul 17;21(8):1140-1143. doi: 10.1093/ntr/nty117. No abstract available.

PMID:
29873768
14.

The Poorest of Poor Suffer the Greatest Burden From Smokeless Tobacco Use: A Study From 140 Countries.

Sinha DN, Gupta PC, Kumar A, Bhartiya D, Agarwal N, Sharma S, Singh H, Parascandola M, Mehrotra R.

Nicotine Tob Res. 2018 Nov 15;20(12):1529-1532. doi: 10.1093/ntr/ntx276.

15.

Defining a global research and policy agenda for betel quid and areca nut.

Mehrtash H, Duncan K, Parascandola M, David A, Gritz ER, Gupta PC, Mehrotra R, Amer Nordin AS, Pearlman PC, Warnakulasuriya S, Wen CP, Zain RB, Trimble EL.

Lancet Oncol. 2017 Dec;18(12):e767-e775. doi: 10.1016/S1470-2045(17)30460-6. Review.

PMID:
29208442
16.

US Adult Interest in Less Harmful and Less Addictive Hypothetical Modified Risk Tobacco Products.

O'Brien EK, Persoskie A, Parascandola M, Hoffman AC.

Nicotine Tob Res. 2018 Sep 25;20(11):1317-1326. doi: 10.1093/ntr/ntx227.

PMID:
29059364
17.

Monitoring harm perceptions of smokeless tobacco products among U.S. adults: Health Information National Trends Survey 2012, 2014, 2015.

Feirman SP, Donaldson EA, Parascandola M, Snyder K, Tworek C.

Addict Behav. 2018 Feb;77:7-15. doi: 10.1016/j.addbeh.2017.09.002. Epub 2017 Sep 9.

18.

Money Gone Up in Smoke: The Tobacco Use and Malnutrition Nexus in Bangladesh.

Husain MJ, Virk-Baker M, Parascandola M, Khondker BH, Ahluwalia IB.

Ann Glob Health. 2016 Sep - Oct;82(5):749-759.e1. doi: 10.1016/j.aogh.2016.07.005.

19.

Analysis of Alkaloids in Areca Nut-Containing Products by Liquid Chromatography-Tandem Mass Spectrometry.

Jain V, Garg A, Parascandola M, Chaturvedi P, Khariwala SS, Stepanov I.

J Agric Food Chem. 2017 Mar 8;65(9):1977-1983. doi: 10.1021/acs.jafc.6b05140. Epub 2017 Feb 23.

20.

Global burden of all-cause and cause-specific mortality due to smokeless tobacco use: systematic review and meta-analysis.

Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal N, Parascandola M, Mehrotra R.

Tob Control. 2018 Jan;27(1):35-42. doi: 10.1136/tobaccocontrol-2016-053302. Epub 2016 Nov 30. Review.

PMID:
27903956
21.

Providing a Science Base for the Evaluation of Tobacco Products.

Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, Myers M, O'Connor RJ, Parascandola M, Rees V, Rice JM, Shields PG.

Tob Regul Sci. 2015 Apr;1(1):76-93.

22.

Tobacco use transitions in the United States: The National Longitudinal Study of Adolescent Health.

Kaufman AR, Land S, Parascandola M, Augustson E, Backinger CL.

Prev Med. 2015 Dec;81:251-7. doi: 10.1016/j.ypmed.2015.08.026. Epub 2015 Sep 9.

23.

Smoke-free air laws and quit attempts: Evidence for a moderating role of spontaneous self-affirmation.

Persoskie A, Ferrer RA, Taber JM, Klein WM, Parascandola M, Harris PR.

Soc Sci Med. 2015 Sep;141:46-55. doi: 10.1016/j.socscimed.2015.07.015. Epub 2015 Jul 20.

PMID:
26246033
24.

Food and Drug Administration tobacco regulation and product judgments.

Kaufman AR, Finney Rutten LJ, Parascandola M, Blake KD, Augustson EM.

Am J Prev Med. 2015 Apr;48(4):445-51. doi: 10.1016/j.amepre.2014.10.026. Epub 2015 Feb 25.

25.

Tobacco use in pregnancy: a window of opportunity for prevention.

Bloch M, Parascandola M.

Lancet Glob Health. 2014 Sep;2(9):e489-e490. doi: 10.1016/S2214-109X(14)70294-3. Epub 2014 Aug 27. No abstract available.

26.

Commentary: Smoking, birthweight and mortality: Jacob Yerushalmy on self-selection and the pitfalls of causal inference.

Parascandola M.

Int J Epidemiol. 2014 Oct;43(5):1373-7. doi: 10.1093/ije/dyu163. No abstract available.

27.

High levels of tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus.

Stepanov I, Gupta PC, Dhumal G, Yershova K, Toscano W, Hatsukami D, Parascandola M.

Tob Control. 2015 Dec;24(e4):e271-4. doi: 10.1136/tobaccocontrol-2014-051744. Epub 2014 Sep 12.

28.

Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch.

Stepanov I, Biener L, Yershova K, Nyman AL, Bliss R, Parascandola M, Hatsukami DK.

Nicotine Tob Res. 2014 Aug;16(8):1070-8. doi: 10.1093/ntr/ntu026. Epub 2014 Mar 6.

29.

A historical review of R.J. Reynolds' strategies for marketing tobacco to Hispanics in the United States.

Iglesias-Rios L, Parascandola M.

Am J Public Health. 2013 May;103(5):e15-27. doi: 10.2105/AJPH.2013.301256. Epub 2013 Mar 14. Review.

30.

Tobacco use among southwestern Alaska Native people.

Renner CC, Lanier AP, Lindgren B, Jensen J, Patten CA, Parascandola M, Benowitz NL, Tyndale RF, Hatsukami DK.

Nicotine Tob Res. 2013 Feb;15(2):401-6. doi: 10.1093/ntr/nts137. Epub 2012 Sep 4.

31.

Food and Drug Administration evaluation and cigarette smoking risk perceptions.

Kaufman AR, Waters EA, Parascandola M, Augustson EM, Bansal-Travers M, Hyland A, Cummings KM.

Am J Health Behav. 2011 Nov;35(6):766-76.

32.

Causes, risks, and probabilities: probabilistic concepts of causation in chronic disease epidemiology.

Parascandola M.

Prev Med. 2011 Oct;53(4-5):232-4. doi: 10.1016/j.ypmed.2011.09.007. Epub 2011 Oct 5.

PMID:
21983603
33.

Tobacco harm reduction and the evolution of nicotine dependence.

Parascandola M.

Am J Public Health. 2011 Apr;101(4):632-41. doi: 10.2105/AJPH.2009.189274. Epub 2011 Feb 17.

34.

Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

O'Connor RJ, Cummings KM, Rees VW, Connolly GN, Norton KJ, Sweanor D, Parascandola M, Hatsukami DK, Shields PG.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3334-48. doi: 10.1158/1055-9965.EPI-09-0429. Review.

35.

Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods.

Rees VW, Kreslake JM, Cummings KM, O'Connor RJ, Hatsukami DK, Parascandola M, Shields PG, Connolly GN.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3225-40. doi: 10.1158/1055-9965.EPI-09-0946. Review.

36.

Methods used in internal industry clinical trials to assess tobacco risk reduction.

Rees VW, Kreslake JM, O'Connor RJ, Cummings KM, Parascandola M, Hatsukami D, Shields PG, Connolly GN.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3196-208. doi: 10.1158/1055-9965.EPI-09-0819. Review.

37.

Clinical trials methods for evaluation of potential reduced exposure products.

Hatsukami DK, Hanson K, Briggs A, Parascandola M, Genkinger JM, O'Connor R, Shields PG.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3143-95. doi: 10.1158/1055-9965.EPI-09-0654. Review.

38.

Characteristics of current and recent former smokers associated with the use of new potential reduced-exposure tobacco products.

Parascandola M, Augustson E, Rose A.

Nicotine Tob Res. 2009 Dec;11(12):1431-8. doi: 10.1093/ntr/ntp157. Epub 2009 Nov 13.

39.

Surveillance indicators for potential reduced exposure products (PREPs): developing survey items to measure awareness.

Bogen K, Biener L, Garrett CA, Allen J, Cummings KM, Hartman A, Marcus S, McNeill A, O'Connor RJ, Parascandola M, Pederson L.

Harm Reduct J. 2009 Oct 19;6:27. doi: 10.1186/1477-7517-6-27.

40.

Consumer awareness and attitudes related to new potential reduced-exposure tobacco product brands.

Parascandola M, Augustson E, O'Connell ME, Marcus S.

Nicotine Tob Res. 2009 Jul;11(7):886-95. doi: 10.1093/ntr/ntp082. Epub 2009 Jun 18.

41.

Criteria for evaluating tobacco control research funding programs and their application to models that include financial support from the tobacco industry.

Cohen JE, Zeller M, Eissenberg T, Parascandola M, O'Keefe R, Planinac L, Leischow S.

Tob Control. 2009 Jun;18(3):228-34. doi: 10.1136/tc.2008.027623. Epub 2009 Feb 24. No abstract available.

42.

Consumer awareness and attitudes related to new potential reduced-exposure tobacco products.

Parascandola M, Hurd AL, Augustson E.

Am J Health Behav. 2008 Jul-Aug;32(4):431-7.

PMID:
18092903
43.

Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds.

White J, Parascandola M, Bero L.

Nicotine Tob Res. 2007 Nov;9(11):1213-25.

PMID:
17978997
45.
48.
49.
50.

Hazardous effects of tobacco industry funding.

Parascandola M.

J Epidemiol Community Health. 2003 Aug;57(8):548-9. No abstract available.

Supplemental Content

Loading ...
Support Center